Analysis of cryoproteins with a focus on cryofibrinogen: a study on 103 patients
Author:
Natali Patrizia1, Debbia Daria1, Cucinelli Maria R.1, Trenti Tommaso1, Amati Gabriele2, Spinella Amelia2, Giuggioli Dilia2, Mascia Maria T.2, Sandri Gilda2
Affiliation:
1. Department of Laboratory Medicine and Pathological Anatomy , Azienda Ospedaliero-Universitaria e Azienda USL di Modena , Modena , Italy 2. Chair of Rheumatology – Department of Maternal, Child and Adult Medical and Surgical Sciences , Università degli Studi di Modena e Reggio Emilia , Modena , Italy
Abstract
Abstract
Objectives
Cryofibrinogen (CF) is an abnormal protein in plasma that precipitates at 4 °C and dissolves at 37 °C. Whilst serum cryoglobulins (CGs) analysis is common practice, CF investigation is rarely performed. This study aims to describe the testing methodology developed at our laboratory, potential pitfalls for all analytical phases, the distribution among hospital wards and clinical conditions underlying test requests and clinical conditions in which to order CF analysis is useful.
Methods
Retrospective analysis of laboratory samples received between January 2019 and June 2021 with CF testing requests.
Results
A complete protocol for CF pre-analytical, analytical and post-analytical phases are supplied. Most test requests were received from the rheumatology department for systemic sclerosis or liver transplant screening. Among the 103 in-patients included, CF+ was confirmed in 68 patients (66%). Of observed CF+ patients (n=68) most cases were CGs− (n=44, 67%). Isolated CF was found in 43% of the cases. Among CF− patients (n=35; 34%) only 2 patients had positive CGs (CGs+). Among rheumatology patients (n=66), isolated CF+ was observed in 45% (n=30/66), whilst among patients with systemic sclerosis with CF+ (n=19), isolated CF+ was detected in 79% (n=15/19).
Conclusions
Described analytical procedures may be used for the creation of harmonized recommendations and indications for CF analysis. Isolated CF positivity among hospitalized patients, predominantly rheumatology and systemic sclerosis patients, appears higher than rates previously reported in literature. We propose CF test recommendations should be included in investigation protocols for diseases where cryofibrinogenemia may occur.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference35 articles.
1. Michaud, M, Pourrat, J. Cryofibrinogenemia. J Clin Rheumatol 2013;19:142–8. https://doi.org/10.1097/rhu.0b013e318289e06e. 2. Blain, H, Cacoub, P, Musset, L, Costedoat-Chalumeau, N, Silberstein, C, Chosidow, O, et al.. Cryofibrinogenaemia: a study of 49 patients. Clin Exp Immunol 2000;120:253–60. https://doi.org/10.1046/j.1365-2249.2000.01210.x. 3. Komp, D, Donaldson, M. The relationship between fibrinogen degradation products and cryofibrinogen. Am J Pediatr Hematol Oncol 1979;1:99. 4. Korst, D, Kratochvil, C. Cryofibrinogen in a case of lung neoplasm associated with thrombophlebitis migrans. Blood 1955;10:945–53. https://doi.org/10.1182/blood.v10.9.945.945. 5. Stathakis, NE, Karamanolis, G, Koukoulis, G, Tsianos, E. Characterization of cryofibrinogen isolated from patients’ plasma. Haemostasis 1981;10:195–202. https://doi.org/10.1159/000214404.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|